Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May;19(5):280-294.
doi: 10.1038/s41585-022-00578-1. Epub 2022 Mar 31.

Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective

Affiliations
Review

Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective

Jeremy Yuen-Chun Teoh et al. Nat Rev Urol. 2022 May.

Abstract

Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic and potentially curative procedure for NMIBC, but has some limitations, including difficulties in ascertaining complete tumour removal upon piecemeal resection and the possibility of tumour re-implantation after the procedure. The oncological control of NMIBC is far from satisfactory, with a 1-year recurrence rate of 15-61%, and a 5-year recurrence rate of 31-78%. Various recurrence mechanisms have been described for NMIBC, such as undetected tumours upon cystoscopy, incomplete resection during TURBT, tumour re-implantation after TURBT, drop metastasis from upper tract urothelial carcinoma and field change cancerization. Understanding the recurrence mechanisms from a clinical perspective has strong implications for the optimization of NMIBC oncological outcomes, as a cure for patients with NMIBC can only be achieved by tackling all possible recurrence mechanisms in a comprehensive manner.

PubMed Disclaimer

References

    1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). - DOI - PubMed
    1. Teoh, J. Y. et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur. Urol. 78, 893–906 (2020). - PubMed - DOI
    1. Pasin, E., Josephson, D. Y., Mitra, A. P., Cote, R. J. & Stein, J. P. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev. Urol. 10, 31–43 (2008). - PubMed - PMC
    1. Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) 2019 update. Eur. Urol. 76, 639–657 (2019). - PubMed - DOI
    1. Khadhouri, S. et al. The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. BJU Int. 128, 440–450 (2021). - PubMed - DOI

LinkOut - more resources